Advert - Allergan Limited – Case AUTH/3431/11/20

Alleged promotion of Botox on LinkedIn and alleged breach of undertaking

Date posted

16 March 2022
Sanction

Advertisement, Public reprimand,
Case number/s

AUTH/3431/11/20 - Complainant v Allergan

For promoting Botox (botulinum toxin type A), a prescription only medicine to the public, on social media, Allergan was ruled in breach of the following clauses of the 2019 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 9.1 - Failing to maintain high standards
Clause 26.1 - Promoting a prescription only medicine to the public

In addition, the Code of Practice Appeal Board required Allergan to be publicly reprimanded for its widespread use of social media which promoted a prescription only medicine to the public.

Advert